These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 24713827)

  • 1. The PCA3 test for guiding repeat biopsy of prostate cancer and its cut-off score: a systematic review and meta-analysis.
    Luo Y; Gou X; Huang P; Mou C
    Asian J Androl; 2014; 16(3):487-92. PubMed ID: 24713827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behavior of the PCA3 gene in the urine of men with high grade prostatic intraepithelial neoplasia.
    Morote J; Rigau M; Garcia M; Mir C; Ballesteros C; Planas J; Raventós CX; Placer J; de Torres IM; Reventós J; Doll A
    World J Urol; 2010 Dec; 28(6):677-80. PubMed ID: 20607245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of Prostate Cancer Antigen 3 and Prostate-Specific Antigen Improves Diagnostic Accuracy in Men at Risk of Prostate Cancer.
    Cao L; Lee CH; Ning J; Handy BC; Wagar EA; Meng QH
    Arch Pathol Lab Med; 2018 Sep; 142(9):1106-1112. PubMed ID: 29547000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer antigen 3 test for prostate biopsy decision: a systematic review and meta analysis.
    Luo Y; Gou X; Huang P; Mou C
    Chin Med J (Engl); 2014; 127(9):1768-74. PubMed ID: 24791889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer gene 3 urine assay cutoff in diagnosis of prostate cancer: a validation study on an Italian patient population undergoing first and repeat biopsy.
    Bollito E; De Luca S; Cicilano M; Passera R; Grande S; Maccagnano C; Cappia S; Milillo A; Montorsi F; Scarpa RM; Papotti M; Randone DF
    Anal Quant Cytol Histol; 2012 Apr; 34(2):96-104. PubMed ID: 22611765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer.
    Wu AK; Reese AC; Cooperberg MR; Sadetsky N; Shinohara K
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):100-5. PubMed ID: 22042252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the diagnostic and predictive power of PCA3 in the prostate cancer. A different best cut-off in each different scenario. Preliminary results.
    Albino G; Capoluongo E; Rocchetti S; Palumbo S; Zuppi C; Cirillo-Marucco E
    Arch Ital Urol Androl; 2014 Dec; 86(4):306-10. PubMed ID: 25641459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.
    Haese A; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Abbou CC; Remzi M; Tinzl M; Feyerabend S; Stillebroer AB; van Gils MP; Schalken JA
    Eur Urol; 2008 Nov; 54(5):1081-8. PubMed ID: 18602209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic value of urine prostate cancer antigen 3 test using a cutoff value of 35 μg/L in patients with prostate cancer.
    Hu B; Yang H; Yang H
    Tumour Biol; 2014 Sep; 35(9):8573-80. PubMed ID: 24863945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of a single PCA3 test before a first negative prostate biopsy: 5-year follow-up].
    Bernardeau S; Charles T; Fromont-Hankard G; Irani J
    Prog Urol; 2017 Apr; 27(5):325-330. PubMed ID: 28385586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additional value of PCA3 density to predict initial prostate biopsy outcome.
    Ruffion A; Perrin P; Devonec M; Champetier D; Decaussin M; Paparel P; Vlaeminck-Guillem V
    World J Urol; 2014 Aug; 32(4):917-23. PubMed ID: 24500192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
    Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
    BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy.
    Scattoni V; Lazzeri M; Lughezzani G; De Luca S; Passera R; Bollito E; Randone D; Abdollah F; Capitanio U; Larcher A; Lista G; Gadda GM; Bini V; Montorsi F; Guazzoni G
    J Urol; 2013 Aug; 190(2):496-501. PubMed ID: 23466239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PCA3: a new tool to diagnose prostate cancer (PCa) and a guidance in biopsy decisions. Preliminary report of the UrOP study.
    Galasso F; Giannella R; Bruni P; Giulivo R; Barbini VR; Disanto V; Leonardi R; Pansadoro V; Sepe G
    Arch Ital Urol Androl; 2010 Mar; 82(1):5-9. PubMed ID: 20593708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.
    Marks LS; Fradet Y; Deras IL; Blase A; Mathis J; Aubin SM; Cancio AT; Desaulniers M; Ellis WJ; Rittenhouse H; Groskopf J
    Urology; 2007 Mar; 69(3):532-5. PubMed ID: 17382159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases.
    Crawford ED; Rove KO; Trabulsi EJ; Qian J; Drewnowska KP; Kaminetsky JC; Huisman TK; Bilowus ML; Freedman SJ; Glover WL; Bostwick DG
    J Urol; 2012 Nov; 188(5):1726-31. PubMed ID: 22998901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reflex PCA3 messenger ribonucleic acid testing: validation of postbiopsy urine samples and correlation with prostate biopsy findings in ∼2000 patients.
    Brown JG; Fulmer JR; Romano J; Pownell J; Rigler W; Wirtshafter A; Sarno M; Shappell SB
    Urology; 2014 Nov; 84(5):1172-80. PubMed ID: 25443926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-time PCR PCA3 assay is a useful test measured in urine to improve prostate cancer detection.
    Foj L; Milà M; Mengual L; Luque P; Alcaraz A; Jiménez W; Filella X
    Clin Chim Acta; 2014 Aug; 435():53-8. PubMed ID: 24803095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.